Cagrilintide

For laboratory research use only by qualified professionals. Not for human or veterinary use. Not for ingestion, injection, topical application, diagnostic, therapeutic, prophylactic or cosmetic use.

Cagrilintide is supplied as a catalogued research material in 5 mg. It is intended only for controlled analytical, biochemical and non-clinical laboratory workflows. The catalogue amount identifies the nominal vial presentation; it is not a dose or a use instruction.

Cagrilintide is a structurally complex 37-residue peptide whose identity depends on sequence, disulfide connectivity, C-terminal amidation and the intact Lys-linked lipid conjugate. Registry data apply only when all of those features and the supplied form match [1–3].

Product identity

Identity must be assigned to the exact batch rather than to a marketed name alone. Sequence, terminal modifications, conjugation, salt or counter-ion, hydration state and excipients may change the applicable mass and registry identifiers. The batch CoA and SDS take precedence over literature identifiers shown below.

Chemical properties and registry information

Where an identifier is qualified or omitted, no unambiguous exact-form public assignment has been confirmed. Do not transfer an identifier from a related analogue, salt, conjugate or formulation.

Research context and evidence status

What the literature supports

Cagrilintide has been characterized as an investigational long-acting amylin analogue in structural, pharmacological and controlled clinical research [2–4].

Evidence limitations

Published phase 2 observations concern a separately manufactured investigational drug and do not establish authorization, batch equivalence, safety or efficacy for this catalogue material [4].

The active catalogue mapping supplied for this update identifies a 5 mg presentation even though the internal product ID contains “10mg”; the visible label and matching CoA must govern.

Technical comparison

The comparison below is limited to structural and analytical distinctions. It does not compare clinical performance or recommend a use.

Quality and batch documentation

Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot or similarly named material must not be treated as evidence for this product.

Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.

Laboratory handling and storage

Store and handle only under the conditions stated on the product label, batch CoA and SDS. Keep the container secured, correctly identified and protected from contamination. Do not infer storage, solvent compatibility or stability from a related compound.

This page intentionally provides no reconstitution, administration or dosing instructions. Laboratory preparation, analytical method selection, risk assessment, personal protective equipment and waste disposal must be defined by the qualified institution and the applicable SDS.

Regulatory and legal status

This catalogue material is not offered as a medicine, medical device, in-vitro diagnostic, food, dietary supplement, cosmetic or veterinary product. It is not intended to diagnose, treat, cure, mitigate or prevent any disease or condition.

A research designation does not override medicinal-product, controlled-substance, chemical, customs or other substance-specific rules. Availability may be restricted by jurisdiction and by the purchaser's verified professional or institutional status.

Sources and references

References document identity and research context only. They do not constitute instructions for use or evidence that this catalogue batch is suitable for any human or veterinary purpose.

1. [1] PubChem. Cagrilintide, CID 171397054.
2. [2] U.S. FDA GSRS. Cagrilintide substance record, UNII AO43BIF1U8.
3. [3] Lau et al. Discovery and characterization of the long-acting amylin analogue cagrilintide (2021).
4. [4] Lau et al. Randomized phase 2 investigation of cagrilintide (2021).

Frequently Asked Questions

What is this material intended for?

Controlled laboratory research by qualified professionals, including substantiated analytical, biochemical or non-clinical workflows. It is not intended for personal use.

Is the amount shown on the vial a dosage?

No. It is a nominal catalogue presentation used to identify the product variant. It is not a dose, concentration, administration schedule or preparation instruction.

Do the CAS number and PubChem CID apply to every batch form?

Only when the exact sequence or structure, termini, conjugation, salt or counter-ion and hydration state match. The batch CoA and SDS govern; a related-compound identifier must not be substituted.

What does an analytical purity result mean?

It is method- and report-specific. For example, an HPLC area percentage is not automatically the same as identity, net content, sterility, endotoxin status or absence of elemental impurities.

How should the material be stored and handled?

Follow the exact label, batch CoA and SDS, together with the institution's risk assessment. This page does not provide reconstitution or administration guidance.

May this material be used in humans or animals?

No. Human and veterinary use, including ingestion, injection, topical application, diagnosis, treatment, prevention and cosmetic use, is expressly excluded.

RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. THE PRODUCT NAME, VIAL AMOUNT AND LITERATURE REFERENCES MUST NOT BE INTERPRETED AS A DOSAGE, ADMINISTRATION INSTRUCTION OR MEDICAL CLAIM.